Business Description
PAVmed Inc
NAICS : 334510
SIC : 3841
ISIN : US70387R4039
Total Employee Number:
41Description
PAVmed Inc. is a commercial-stage medical technology company that develops and commercializes products through a portfolio of subsidiaries. Its diagnostics business, Lucid Diagnostics, markets EsoCheck, a non-invasive esophageal cell collection device, and EsoGuard, a laboratory test used to detect Barrett's esophagus and early esophageal cancer in patients with chronic heartburn. Its medical device subsidiary, Veris Health, offers the Veris Cancer Care Platform, a remote patient monitoring and digital health system for cancer patients. PAVmed also has earlier-stage device programs, including carpometacarpal arthroplasty and infusion therapy technologies. Revenue comes primarily from sales of diagnostic products and laboratory testing services, along with device sales, in the United States, with the company targeting the gastroenterology and oncology markets through direct sales and partnerships.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.22 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.49 | |||||
Debt-to-EBITDA | -1.05 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -9.34 | |||||
Beneish M-Score | 37.25 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -61.8 | |||||
3-Year EBITDA Growth Rate | 80.9 | |||||
3-Year EPS without NRI Growth Rate | 30.7 | |||||
3-Year FCF Growth Rate | 72.3 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 24.36 | |||||
9-Day RSI | 29.24 | |||||
14-Day RSI | 34.3 | |||||
3-1 Month Momentum % | -6.33 | |||||
6-1 Month Momentum % | 48.49 | |||||
12-1 Month Momentum % | 48.49 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.19 | |||||
Quick Ratio | 1.14 | |||||
Cash Ratio | 0.93 | |||||
Days Inventory | 242.38 | |||||
Days Sales Outstanding | 37.8 | |||||
Days Payable | 700.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -64.1 | |||||
Shareholder Yield % | 17.31 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -220.54 | |||||
Operating Margin % | -23131.25 | |||||
Net Margin % | -10794.64 | |||||
EBITDA Margin % | -14583.04 | |||||
FCF Margin % | -6892.66 | |||||
OCF Margin % | -6846.5 | |||||
ROE % | -32.66 | |||||
ROA % | -29.29 | |||||
ROIC % | -61.25 | |||||
3-Year ROIIC % | 2240.34 | |||||
ROC (Joel Greenblatt) % | -788.36 | |||||
ROCE % | -50.39 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 47.11 | |||||
PB Ratio | 0.92 | |||||
Price-to-Tangible-Book | 0.92 | |||||
EV-to-EBIT | -2.49 | |||||
EV-to-EBITDA | -2.52 | |||||
EV-to-Forward-EBITDA | -6.03 | |||||
EV-to-Revenue | 366.29 | |||||
EV-to-Forward-Revenue | 112.22 | |||||
EV-to-FCF | -5.49 | |||||
Price-to-GF-Value | 3.29 | |||||
Earnings Yield (Greenblatt) % | -40.06 | |||||
FCF Yield % | -19.73 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PAVmed Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.096 | ||
| EPS (TTM) (€) | -14.101 | ||
| Beta | 2.2973 | ||
| 3-Year Sharpe Ratio | 0.32 | ||
| 3-Year Sortino Ratio | 1.46 | ||
| Volatility % | 184.41 | ||
| 14-Day RSI | 34.3 | ||
| 14-Day ATR (€) | 0.183183 | ||
| 20-Day SMA (€) | 3.96375 | ||
| 12-1 Month Momentum % | 48.49 | ||
| 52-Week Range (€) | 2.63999 - 7.371 | ||
| Shares Outstanding (Mil) | 9.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PAVmed Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PAVmed Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 08:30 | In 53 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 52 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 08:30 | 3.96 (+12.68%) | ||
| Second quarter earnings results for 2026 | 2026-08-14 | 3.96 (+12.68%) | ||
| Canaccord Genuity 46th Annual Growth Conference | 2026-08-11 11:30 | 3.94 (+0.00%) | ||
| General meeting for 2026 | 2026-06-24 10:00 | 4.14 (+0.36%) | ||
| First quarter earnings conference call for 2026 | 2026-05-15 08:30 | 5.18 (+0.19%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 5.18 (+0.19%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-16 10:15 | 2.74 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-30 08:30 | 2.74 (+0.00%) |
Show
Entries
PAVmed Inc Frequently Asked Questions
What is PAVmed Inc(FRA:1P5)'s stock price today?
The current price of FRA:1P5 is €3.32. The 52 week high of FRA:1P5 is €7.37 and 52 week low is €2.64.
When is next earnings date of PAVmed Inc(FRA:1P5)?
The next earnings date of PAVmed Inc(FRA:1P5) is 2026-11-13 Est..
Does PAVmed Inc(FRA:1P5) pay dividends? If so, how much?
PAVmed Inc(FRA:1P5) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers